L-Annamycin + Cytarabine in Relapsed/Refractory AML

Market
100%75%50%25%0%Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.8%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19Apr 19 • YES 49.7%Apr 19
Trade

Will this trial meet its primary endpoint?

Paper Trading
Create account to trade
DetailsModel PositionsModel SnapshotsOracle
NO DECISIONPending Review80% confidenceGrok 4.20 (xAI)
Question
Will this trial meet its primary endpoint?
Found
Summary

Preliminary blinded 40% CRc rate (n=30) in MIRACLE trial framed as encouraging early signal but incomplete; unblinded 45-pt interim vs placebo due mid-2026. No full efficacy readout yet.

Sources
Web Searchmoleculin.com
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

Preliminary blinded CRc rate of 40% (30% CR, 10% CRh) in first 30 pts; encouraging early signals in difficult-to-treat R/R AML population.

Web Searchrarecancernews.com
Annamycin shows encouraging early results in Phase 2/3 AML clinical trial

40% composite remission rate in early interim data from MIRACLE trial (NCT06788756) in relapsed/refractory AML.

NO DECISIONDismissed80% confidenceGrok 4.20 (xAI)
Question
Will this trial meet its primary endpoint?
Found
Reviewed
Summary

No unblinded readout for NCT06788756 MIRACLE primary endpoint vs placebo. Preliminary blinded 40% CRc (n=30) framed as encouraging vs historical but incomplete; interim unblinding pending mid-2026.

Sources
Web Searchmoleculin.com
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Blinded preliminary CRc rate 40% (30% CR + 10% CRh) in first 30 subjects; 67% improvement over historical cytarabine response.

Web Searchbiospace.com
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

45-subject interim unblinding on track for mid-2026; early blinded results show 40% remission rate in difficult-to-treat population.

Stats
Latest Run
Model
Grok 4.20 (xAI)
Runs
2 runs